Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...
Những tác giả chính: | Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
Wiley
2021-08-01
|
Loạt: | ACR Open Rheumatology |
Truy cập trực tuyến: | https://doi.org/10.1002/acr2.11259 |
Những quyển sách tương tự
-
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
Bằng: Tore K Kvien, et al.
Được phát hành: (2019-05-01) -
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Bằng: Vivian P. Bykerk, et al.
Được phát hành: (2023-02-01) -
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
Bằng: Jeffrey R. Curtis, et al.
Được phát hành: (2017-12-01) -
Certolizumab pegol in the treatment of spondyloarthritis
Bằng: Mariusz Korkosz
Được phát hành: (2014-09-01) -
CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
Bằng: Sh. F. Erdes
Được phát hành: (2016-02-01)